Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels

Unintended block of HERG K+ channels is a side effect of many common medications and is the most common cause of acquired long QT syndrome associated with increased risk of life-threatening arrhythmias. The molecular mechanism of high-affinity HERG block by structurally diverse compounds has been attributed to π-stacking and cation-π interactions of a drug (e.g., cisapride) with specific aromatic amino acid residues (Tyr-652 and Phe-656) in the S6 α-helical domain that face the central cavity of the channel. It also has been proposed that strong C-type inactivation of HERG facilitates or is the primary determinant of high-affinity drug binding. The structurally related, but noninactivating eag channel is insensitive to HERG blockers unless inactivation is induced by specific amino acid mutations [Ficker, E., Jarolimek, W. & Brown, A. M. (2001) Mol. Pharmacol. 60, 1343–1348]. Here we examine the relative importance of inactivation vs. positioning of S6 aromatic residues in determining sensitivity of HERG and eag channels to block by cisapride. The repositioning of Tyr-652 or Phe-656 along the S6 α-helical domain of HERG reduced sensitivity of channels to block by cisapride. Moreover, independent of inactivation, repositioning of the equivalent aromatic residues in Drosophila eag channels induced sensitivity to block by cisapride. These findings suggest that positioning of S6 aromatic residues relative to the central cavity of the channel, not inactivation per se determines drug block of HERG or eag channels.

[1]  B. Hille,et al.  Local anesthetics: hydrophilic and hydrophobic pathways for the drug- receptor reaction , 1977, The Journal of general physiology.

[2]  B. Katzung,et al.  Antiarrhythmic agents: the modulated receptor mechanism of action of sodium and calcium channel-blocking drugs. , 1984, Annual review of pharmacology and toxicology.

[3]  D. Zipes Proarrhythmic effects of antiarrhythmic drugs. , 1987, The American journal of cardiology.

[4]  G. Sarkar,et al.  The "megaprimer" method of site-directed mutagenesis. , 1990, BioTechniques.

[5]  A. L. Goldin,et al.  Preparation of RNA for injection into Xenopus oocytes. , 1992, Methods in enzymology.

[6]  Walter Stühmer,et al.  Electrophysiological recording from Xenopus oocytes. , 1992, Methods in enzymology.

[7]  R. Aldrich,et al.  Effects of external cations and mutations in the pore region on C-type inactivation of Shaker potassium channels. , 1993, Receptors & channels.

[8]  G. Robertson,et al.  HERG, a human inward rectifier in the voltage-gated potassium channel family. , 1995, Science.

[9]  M. Sanguinetti,et al.  A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channel , 1995, Cell.

[10]  E. Green,et al.  A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome , 1995, Cell.

[11]  Gary Yellen,et al.  The inward rectification mechanism of the HERG cardiac potassium channel , 1996, Nature.

[12]  R Lazzara,et al.  Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. , 1996, Circulation.

[13]  J. López-Barneo,et al.  Pore mutations in Shaker K+ channels distinguish between the sites of tetraethylammonium blockade and C‐type inactivation. , 1997, The Journal of physiology.

[14]  H. Strauss,et al.  Modulation of HERG affinity for E‐4031 by [K+]o and C‐type inactivation , 1997, FEBS letters.

[15]  L. Kiss,et al.  Modulation of C-type inactivation by K+ at the potassium channel selectivity filter. , 1998, Biophysical journal.

[16]  A. Brown,et al.  Molecular determinants of dofetilide block of HERG K+ channels. , 1998, Circulation research.

[17]  G. Robertson,et al.  Transfer of rapid inactivation and sensitivity to the class III antiarrhythmic drug E‐4031 from HERG to M‐eag channels , 1998, The Journal of physiology.

[18]  E. Perozo,et al.  Structural rearrangements underlying K+-channel activation gating. , 1999, Science.

[19]  Jun Chen,et al.  A structural basis for drug-induced long QT syndrome. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[20]  John S. Mitcheson,et al.  Trapping of a Methanesulfonanilide by Closure of the Herg Potassium Channel Activation Gate , 2000, The Journal of general physiology.

[21]  J. Balser,et al.  Probing the Interaction Between Inactivation Gating and d-Sotalol Block of HERG , 2000, Circulation research.

[22]  W. Crumb,et al.  Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias , 2000, Expert opinion on pharmacotherapy.

[23]  H. Duff,et al.  Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites. , 2000, Molecular pharmacology.

[24]  M. Sanguinetti,et al.  Molecular and Cellular Mechanisms of Cardiac Arrhythmias , 2001, Cell.

[25]  A. Brown,et al.  Molecular determinants of inactivation and dofetilide block in ether a-go-go (EAG) channels and EAG-related K(+) channels. , 2001, Molecular pharmacology.

[26]  H. Witchel,et al.  Inhibition of HERG potassium channel current by the class 1a antiarrhythmic agent disopyramide. , 2001, Biochemical and biophysical research communications.

[27]  I Kodama,et al.  Open channel block of HERG K(+) channels by vesnarinone. , 2001, Molecular pharmacology.

[28]  Eduardo Perozo,et al.  Structure of the KcsA channel intracellular gate in the open state , 2001, Nature Structural Biology.

[29]  Youxing Jiang,et al.  The open pore conformation of potassium channels , 2002, Nature.

[30]  Youxing Jiang,et al.  Crystal structure and mechanism of a calcium-gated potassium channel , 2002, Nature.